ABHD6

ABHD6, also known as alpha/beta-hydrolase domain-containing protein 6, is a transmembrane serine hydrolase that plays a crucial role in the regulation of endocannabinoid signaling. It hydrolyzes 2-arachidonylglycerol (2-AG), a key lipid mediator in the central nervous system (CNS). ABHD6 is involved in synaptic plasticity, neuroinflammation, and energy homeostasis, and its dysregulation is associated with neurological diseases such as epilepsy, multiple sclerosis, and psychiatric disorders. The protein interacts with various signaling pathways, including the endocannabinoid system, AMPA receptors, and carnitine palmitoyl transferase 1c (CPT1c), and its inhibition has potential therapeutic implications for treating these conditions.
ABHD6's role in lipid metabolism and its interaction with the endocannabinoid system highlight its potential as a therapeutic target for metabolic diseases like obesity and type 2 diabetes. Research on ABHD6 inhibitors is ongoing, with promising results in preclinical studies, suggesting a promising direction for drug development in the treatment of CNS and metabolic disorders.